|
SI23170A
|
|
Polymeric delivery formulations of leuprolide with improved efficacy
|
|
CN102112107A
|
|
Controlled release copolymer formulation with improved release kinetics
|
|
US2008268021A1
|
|
Adhesive bioerodible ocular drug delivery system
|
|
CA2678176A1
|
|
Sustained delivery formulations of rapamycin compounds
|
|
WO2008100532A1
|
|
Low burst poly-(lactide/glycolide) and methods to produce polymers
|
|
CA2666341A1
|
|
Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
|
|
US2007142317A1
|
|
Topical composition for treatment of skin disorders
|
|
AU2005316545A1
|
|
Sustained delivery formulations of octreotide compounds
|
|
WO2006053175A2
|
|
A stabilized polymeric delivery system
|
|
WO2006050303A2
|
|
Intravaginal treatment of vaginal infections with metronidazole compositions
|
|
WO2006042324A2
|
|
Antifungal composition applicable to body tissue, preferably nails
|
|
CN101437478A
|
|
Ocular delivery of polymeric delivery formulations
|
|
AU2005294382A1
|
|
Ocular delivery of polymeric delivery formulations
|
|
MXPA06001776A
|
|
Adhesive bioerodible transmucosal drug delivery system.
|
|
EP1675563A1
|
|
Emulsive composition containing dapsone
|
|
EP1567173A2
|
|
A protectant for uv-induced skin damage
|
|
US2004009609A1
|
|
Method for lyophilizing an active agent
|
|
EA008022B1
|
|
Method for topical use of dapsone for the treatment of ache
|
|
EP1269096A1
|
|
System and method for lyophilizing a pharmaceutical solution
|
|
US7128927B1
|
|
Emulsions for in-situ delivery systems
|
